AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative interview
Description: Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
Study NCT05887271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative interview
Description: Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skeletal muscle magnetic resonance spectroscopy
Description: Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.
Study NCT05887271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle magnetic resonance spectroscopy
Description: Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.
Study NCT06576960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano silver fluoride varnish and tri calcium phosphate varnish
Description: Fluoride varnishes
Study NCT05404646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy
Description: Thoracic mobility exercises These techniques include mobilization, manipulation and glides to check and treat the joints. Here, these techniques will be used to mobilize the thoracic spine. In this treatment mobility exercises (Unilateral posterior anterior, Central posterior anterior and transverse glides) + hot pack (10 min) + neck stretching (neck flexors, extensors, side benders) + cervical Traction will be given to patient. A total session time will be 45 min and thrice a week on alternate days for three weeks.
Study NCT05404646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy
Description: Thoracic stretching exercises Thoracic stretching exercises. Thoracic stretching exercises are used to correct the musculature of thoracic region. In this treatment group stretching exercises (passive stretches and therapist facilitated exercises) +hot pack (10 min) +neck stretching (neck flexors, extensors, side benders) + tractions will be given to patient. A total of 45 min session thrice a week on alternate days for three weeks will be given. Only the eligible patients who fulfil the inclusion criteria will be included in the study.
Study NCT06014138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
Study NCT06014138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
Study NCT04750265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted early mobilization
Description: Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
Study NCT05127213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon system
Description: Intragastric balloon system (PA450) developed and produced by Changzhou Zhishan Medical Technology Co., Ltd. It is a swallowable capsule intragastric balloon.The degradable material on the intragastric balloon can be degraded naturally, and the balloon is naturally discharged from the body through the gastrointestinal tract
Study NCT05127213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy is the use of laparoscopy to cut out the greater curvature of the stomach, mainly for weight loss.
Study NCT06437717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of different topical nasal solutions
Description: each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients
Study NCT06208085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avocado
Description: Intervention arm
Study NCT04953910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study NCT04953910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study NCT06565611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bremelanotide
Description: bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
Study NCT06565611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bremelanotide
Description: bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
Study NCT06565611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tirzepatide
Description: tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
Study NCT06565611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirzepatide
Description: tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
Study NCT06400537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-319
Description: A-319 will be dosed according to the assigned group.
Study NCT06626373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry Juice
Description: Participants will consume elderberry juice 1-week.
Study NCT06626373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Participants will consume placebo beverage twice/day for 1-week.
Study NCT06624774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: The structured exercise sessions will be conducted in a homebased setting, consisting of 8 resistance exercises (RE). The 8 RE's will include 4 upper body and 4 lower body exercises (Sit to stand, chest press, heel raises, bicep curls, leg abduction, tricep kickbacks, lunges, mid row). This is adapted from an existing home-based trial in cardiac patients. In addition, the structured exercise programme will include a walking programme. Participants will receive a Fitbit charge 5 activity monitor. Additionally, participants will conduct daily IMT via a Powerbreathe medic plus device. Participants will conduct 6 sets of 6 breaths at 50% of peak inspiratory pressure that has been measured at baseline. Education will be delivered via pre-recorded videos or in person
Study NCT06625619 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06624891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perioperative fluid responsiveness with the Pleth variability index
Description: Perioperative fluid challenge and responsiveness will be based on monitoring the pleth variability index. In fact, volemia will be estimated with the PVI.
Study NCT06624891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perioperative fluid responsiveness with delta PP
Description: fluid challenge and responsiveness during intervention will be based on monitoring delta PP.
Study NCT06625034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06625034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06625034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06625034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06625034 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Beam Radiation Therapy
Description: Undergo radiation therapy
Study NCT06625034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo radiation therapy
Study NCT06625034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06625034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06625034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06625034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06625034 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Receive human-driven treatment planning
Study NCT06625034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Receive RapidPlan treatment planning
Study NCT04814654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHALO! 2.0
Description: The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers.
Study NCT04814654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-matched control (AMC)
Description: The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers.
Study NCT04814654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital coupon only (DCO)
Description: The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers.
Study NCT06205316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive ADT
Study NCT06205316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06205316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06205316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT06205316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06205316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT06205316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06205316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study NCT06695026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 1
Description: RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
Study NCT06695026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 2
Description: RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
Study NCT06695026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 3
Description: RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
Study NCT06627244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
Study NCT06627244 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Description: Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
Study NCT06688201 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Other neurosurgical techniques
Description: Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.
Study NCT06688201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Soft Channel Brain Haemorrhage Evacuation
Description: This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
Study NCT06757504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01 Tablets (12mg or 18mg)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Study NCT06757504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Study NCT06757504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Study NCT06760793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual static stretching exercises on plantar flexors
Description: A manual static stretching exercises was performed on the plantar flexors in both knee extension and flexion. The stretch was applied while the participant was in a prone position
Study NCT06760793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction massage on plantar flexors
Description: Deep Friction Massage was applied to both the gastrocnemius muscle and the Achilles tendon. Participants were positioned in a prone posture for both applications
Study NCT06759077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Description: adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL A
Description: A 30-minute COR ECG recording will be performed, including 15 minutes of continuous sitting data used for clinical indication analysis through CardioMIND software. Data collection can occur in-clinic, via PHS, or using a shipped device with telehealth support. Sleep, HRV, and AFIB risk analysis will not be included.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL B
Description: Subjects will undergo 24 hours of COR ECG recording, which must include at least one 15-minute unsupervised sitting session. Data analysis will include sleep patterns, HRV, and AFIB risk. ECG acquisition may take place in-clinic, via Patient Home Setup (PHS), or with a shipped device.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL C
Description: COR 1.0 ECG recordings will be conducted over 2 to 7 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants subjects will also wear a cleared wrist or finger device to track SpO2 during sleep. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL D
Description: COR 2.0 (CORMDX) recordings will be conducted over 2 to 14 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants will also wear a cleared wrist or finger device to track SpO2 during sleep nights. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL E
Description: Subjects will complete a 30-minute CORMDx (COR 2.0) ECG recording, with 15 minutes of continuous sitting data used for clinical indication analysis. Sleep, HRV, and AFIB risk analysis will not be performed.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL F
Description: A 30-minute COR 2.0 ECG recording will be completed, along with a 12-lead resting ECG using an FDA-cleared reference device. Sleep, HRV, and AFIB analysis will not be performed.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL G
Description: A 40-minute COR 2.0 recording will be conducted in two phases: 15 minutes of upright sitting and 15 minutes in a supine position. Hemodynamic monitoring, including blood pressure, cardiac output, and stroke volume variation, will be conducted using an FDA-cleared reference device. No sleep, HRV, or AFIB analysis will be performed.
Study NCT06763549 — intervention group
Intervention type: DEVICE
Intervention: SUBPROTOCOL H
Description: Subjects will undergo a 40-minute COR 2.0 recording, followed by a 40-minute COR 1.0 recording. Hemodynamic monitoring using an FDA-cleared reference device will be performed during both sessions. The transition between devices must occur within 60 minutes if the same adhesive is reused. Sleep, HRV, and AFIB analysis will not be performed.
Study NCT06760325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tidal Model Intervention
Description: The model emphasizes long-term developmental care, extending support from hospital to home after discharge. This approach equips individuals with skills to understand and address challenges, emphasizing therapeutic interventions and sustained support through professionals or community groups. By focusing on the chaos and tide concepts of the Tidal Model, psychosocial interventions aim to enhance independence, manage symptoms, and improve quality of life.~In this arm, Tidal Model-based approaches will be applied during home visits to COPD patients. Within the scope of the intervention, psychosocial needs of patients will be assessed, individualized care plans will be created and symptom management and independence will be promoted by focusing on the chaos and tide concepts of the Tidal Model.
Study NCT06762210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI Molar Mind
Description: a baseline oral health assessment using AI Molar Mind, which analyzes intraoral images and self-reported oral health data.
Study NCT06764056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.